Acute Coronary SyndromeNCT06673381
High Sensitive C-reactive Protein to Albumin Ratio in Acute Coronary Syndrome
An observational study of Acute Coronary Syndrome, run by Sohag University at 1 site in Egypt.
Trial summary
assess the use of hs- C-reactive protein to albumin ratio (hs-CAR) in prediction of in-hospital short-term major adverse cardiac events (MACEs) in acute coronary syndrome (ACS) patients Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Coronary Syndrome
- How many people
- 240 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Nov 2024to 1 Oct 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: It included patients with ACS diagnosed according to AHA/ACCF guidelines according to symptoms, ECG findings and serum troponin levels), who had admitted to the CCU.
Who may be able to join
- All patients aged 18 Year or older presented by ACS not candidet for primary percutaneus coronary intervention ( PCI ) .
Who cannot join
- • Patients aged < 18 years old
- Patients who have eGFR <60 ml/kg /m2
- Patients who have malignancies
- Patients who have chronic heart failure (NYHA class >II)
- Pateints who have chronic liver disease
- Patients who have nephrotic syndrome
Show all 9Show fewer
- Patients who have acute cerebrovascular stroke
- Pregnant women
- Patients who have recent infection
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site, 1 recruiting
- Recruiting
Sohag faculty of medicine
Sohag
Amira Elbasuony, 01113695925
About this study
Official title: Prediction of Acute Coronary Syndrome In-hospital Major Adverse Cardiovascular Events by High Sensitivity C- Reactive Protein to Albumin Ratio
assess the use of hs- C-reactive protein to albumin ratio (hs-CAR) in prediction of in-hospital short-term major adverse cardiac events (MACEs) in acute coronary syndrome (ACS) patients
Read the detailed description
Observational study conducted at coronary care unit(CCU) in sohag university hospital It included patients with ACS diagnosed according to AHA/ACCF guidelines (according to symptoms, ECG findings and serum troponin levels), who had admitted to the CCU.
Venous blood samples were instantly collected on admission to the hospital. hs-CRP , serum albumin level were measured.
hs-CAR is calculated and the patients divided into two groups: Group A ( patients with high hs-CAR) and group B ( patients with low hs-CAR) In-hospital MACE was regarded as the end point of our study. It was defined as acute heart failure, cardiogenic shock, reinfarction, all-cause death, serious arrhythmia and cardiac death
- Conditions
- Acute Coronary Syndrome
- Keywords
- high sensitive c-reactive protein to albumin ratio
- Medical subject headings
- Acute Coronary Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| high sensitive c-reactive protein to albumin ratio (hs-CAR) | Group A ( patients with high hs-CAR) and group B ( patients with low hs-CAR) |
What is being measured
The primary outcome is the main question the study is designed to answer.
assess the use of hs- C-reactive protein to albumin ratio (hs-CAR) in acute coronary syndrom patients
Venous blood samples were collected on admission to the hospital. hs-CRP , serum albumin level were measured.
hs-CAR is calculated and the patients divided into two groups: Group A ( patients with high hs-CAR) and group B ( patients with low hs-CAR)
Measured: at time of admission in hospital
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Nov 2024
- Study start1 Nov 2024
- Primary completion1 Nov 2024
- Study completion1 Oct 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Coronary SyndromeStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 240 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Amira Elbasuony Morsy, Sohag University
- Investigators
- Amira Elbasuony, resident, Principal investigator, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06673381
- Sponsor's protocol ID
- AEMorsy
- Status last verified
- Nov 2024
- First submitted
- 1 Nov 2024
- Last updated
- 4 Nov 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 4 Nov 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prediction of Acute Coronary Syndrome In-hospital Major Adverse Cardiovascular Events by High Sensitivity C- Reactive Protein to Albumin Ratio
- ClinicalTrials.gov ID
- NCT06673381
- Acronym / sponsor ID
- AEMorsy
- Conditions
- Acute Coronary Syndrome
- Keywords
- high sensitive c-reactive protein to albumin ratio
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 240 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 1 Nov 2024 (actual)
- Primary completion
- 1 Nov 2024 (actual)
- Study completion
- 1 Oct 2025 (estimated)
- First posted
- 4 Nov 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
assess the use of hs- C-reactive protein to albumin ratio (hs-CAR) in prediction of in-hospital short-term major adverse cardiac events (MACEs) in acute coronary syndrome (ACS) patients
Detailed description
Observational study conducted at coronary care unit(CCU) in sohag university hospital It included patients with ACS diagnosed according to AHA/ACCF guidelines (according to symptoms, ECG findings and serum troponin levels), who had admitted to the CCU.
Venous blood samples were instantly collected on admission to the hospital. hs-CRP , serum albumin level were measured.
hs-CAR is calculated and the patients divided into two groups: Group A ( patients with high hs-CAR) and group B ( patients with low hs-CAR) In-hospital MACE was regarded as the end point of our study. It was defined as acute heart failure, cardiogenic shock, reinfarction, all-cause death, serious arrhythmia and cardiac death
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| high sensitive c-reactive protein to albumin ratio (hs-CAR) | – | –Group A ( patients with high hs-CAR) and group B ( patients with low hs-CAR) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- It included patients with ACS diagnosed according to AHA/ACCF guidelines according to symptoms, ECG findings and serum troponin levels), who had admitted to the CCU.
Key inclusion criteria (1 listed)
- All patients aged 18 Year or older presented by ACS not candidet for primary percutaneus coronary intervention ( PCI ) .
Key exclusion criteria (9 listed)
- • Patients aged < 18 years old
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
assess the use of hs- C-reactive protein to albumin ratio (hs-CAR) in acute coronary syndrom patients
Time frame: at time of admission in hospital
Venous blood samples were collected on admission to the hospital. hs-CRP , serum albumin level were measured. hs-CAR is calculated and the patients divided into two groups: Group A ( patients with high hs-CAR) and group B ( patients with low hs-CAR)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Nov 2024.
- Individual participant dataSharing planned: Undecided
Related trials for Acute Coronary Syndrome
Recruiting
CT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes
Coronary Artery Disease, Chest Syndrome
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
RecruitingPhase 4
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
Acute Coronary Syndromes, STEMI
Recruiting
AI-Assisted Interpretation of Cardiac CT in the Emergency Department
Chest Pain, Acute Coronary Syndrome
Enrolling by invitation
Optical Coherence Tomography in Acute Vessel Evaluation
Ischemic Heart Disease, Ischemic Coronary Artery Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Amira Elbasuony, resident principal investigator
Sohag University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Coronary Syndrome, run by Sohag University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Amira Elbasuony, resident (01113695925, amiraelbadawy518@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
assess the use of hs- C-reactive protein to albumin ratio (hs-CAR) in acute coronary syndrom patients (time frame: at time of admission in hospital). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Nov 2024.